Literature DB >> 27127151

Salvage High-dose-rate Interstitial Brachytherapy for Pelvic Recurrent Cervical Carcinoma After Hysterectomy.

Naoya Murakami1, Tomoyasu Kato2, Yuichiro Miyamoto3, Satoshi Nakamura4, Akihisa Wakita4, Hiroyuki Okamoto4, Keisuke Tsuchida4, Tairo Kashihara4, Kazuma Kobayashi4, Ken Harada4, Mayuka Kitaguchi4, Shuhei Sekii4, Kana Takahashi4, Rei Umezawa4, Koji Inaba4, Yoshinori Ito4, Hiroshi Igaki4, Jun Itami4.   

Abstract

BACKGROUND: The aim of this study was to report the clinical results of salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with cervical cancer with pelvic recurrence after hysterectomy. PATIENTS AND METHODS: When there was no indication for total pelvic extenteration (TPE) and the tumor depth was more than 5 mm of invasion in the paracolpium, salvage HDR-ISBT was applied.
RESULTS: A total of 26 patients were included in this study. The median number of fractions and dose per fraction of HDR-ISBT were 5 (range=3-20 fractions) and 6 Gy (range=2.5-6 Gy), respectively. Three-year local control, progression-free survival, and overall survival were 51.1%, 34.4% and 57.1%, respectively. Combination of external-beam radiation therapy, clinical target volume D90 greater than 65 Gy, and dose per fraction greater than 5 Gy were associated with favorable local control.
CONCLUSION: For patients with recurrent cervical cancer post hysterectomy who are not candidates for TPE, salvage HDR-ISBT is a possible curative treatment modality. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Salvage interstitial brachytherapy; high-dose-rate interstitial brachytherapy; post hysterectomy relapse; uterine cervical cancer

Mesh:

Year:  2016        PMID: 27127151

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer.

Authors:  Naoya Murakami; Kazuma Kobayashi; Tomoyasu Kato; Satoshi Nakamura; Akihisa Wakita; Hiroyuki Okamoto; Satoshi Shima; Keisuke Tsuchida; Tairo Kashihara; Ken Harada; Kana Takahashi; Rei Umezawa; Koji Inaba; Yoshinori Ito; Hiroshi Igaki; Jun Itami
Journal:  J Contemp Brachytherapy       Date:  2016-10-10

2.  Selection of Treatment Regimens for Recurrent Cervical Cancer.

Authors:  Xiaopei Chao; Xiaochen Song; Huanwen Wu; Yan You; Ming Wu; Lei Li
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

3.  Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy.

Authors:  Yanhao Liu; Ping Jiang; Haichen Zhang; Junjie Wang
Journal:  J Gynecol Oncol       Date:  2020-11-25       Impact factor: 4.401

4.  Outcomes of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer.

Authors:  Shuhei Sekii; Naoya Murakami; Tomoyasu Kato; Ken Harada; Mayuka Kitaguchi; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Yoshinori Ito; Ryohei Sasaki; Jun Itami
Journal:  J Contemp Brachytherapy       Date:  2017-05-18

5.  Prospective observational study on the safety of an original fiducial marker insertion for radiotherapy in gynecological cancer by a simple method.

Authors:  Shuhei Sekii; Kayoko Tsujino; Hikaru Kubota; Satoshi Yamaguchi; Kengo Kosaka; Shuichiro Miyazaki; Nor Shazrina Sulaiman; Yoko Matsumoto; Yosuke Ota; Toshinori Soejima; Ryohei Sasaki
Journal:  J Radiat Res       Date:  2019-11-22       Impact factor: 2.724

6.  The Preliminary Results of 3-Dimensional Printed Individual Template Assisted 192Ir High-Dose Rate Interstitial Brachytherapy for Central Recurrent Gynecologic Cancer.

Authors:  Ping Jiang; Ang Qu; Shuhua Wei; Haitao Sun; Xile Zhang; Xu Li; Junjie Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.